دورية أكاديمية
MR spectroscopy of the liver - a reliable non-invasive alternative for evaluating non-alcoholic fatty liver disease.
| العنوان: | MR spectroscopy of the liver - a reliable non-invasive alternative for evaluating non-alcoholic fatty liver disease. |
|---|---|
| المؤلفون: | Lăpădat AM; Department of Radiology and Medical Imaging, Department of Medical Informatics, University of Medicine and Pharmacy of Craiova, Romania; lucian.florescu@umfcv.ro, catalin.manea@umfcv.ro., Florescu LM, Manea NC, Gheonea DI, Pirici D, Tudoraşcu DR, Ene R, Gheonea IA |
| المصدر: | Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie [Rom J Morphol Embryol] 2020; Vol. 61 (1), pp. 73-80. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Editura Academiei Române Country of Publication: Romania NLM ID: 9112454 Publication Model: Print Cited Medium: Internet ISSN: 2066-8279 (Electronic) Linking ISSN: 12200522 NLM ISO Abbreviation: Rom J Morphol Embryol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Bucuresti, România : Editura Academiei Române, [1990- |
| مواضيع طبية MeSH: | Liver/*pathology , Magnetic Resonance Spectroscopy/*methods , Non-alcoholic Fatty Liver Disease/*diagnosis , Non-alcoholic Fatty Liver Disease/*diagnostic imaging, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult |
| مستخلص: | Non-alcoholic fatty liver disease (NAFLD) is one of the most common conditions worldwide that targets the liver parenchyma. NAFLD represents an intrahepatic triglyceride accumulation in the absence of excessive alcohol consumption and other diseases that affect the liver parenchyma. The current "gold standard" for evaluating the amount of intrahepatic fat is represented by liver biopsy, but many patients are reluctant and hardly accept undergoing this procedure due to its invasive nature. The current study addresses this aspect by evaluating the reliability of liver magnetic resonance spectroscopy (MRS) in diagnosing NAFLD, compared to the traditional invasive liver biopsy. The present study included a total of 38 patients based on several well-defined inclusion and exclusion criteria. We used the same NAFLD grading system for both liver MRS and liver biopsy: grade 0: <5% hepatocytes are affected; grade I: 5-33% hepatocytes are affected; grade II: 34-66% hepatocytes are affected; grade III: >66% hepatocytes are affected. Regarding the NAFLD grade, over three-quarters of patients were classified as grade I and grade II, with a strong predilection for men. The current results indicated a significant association between the NAFLD grade indicated by liver MRS and the NAFLD grade indicated by liver biopsy. At the end of our study, we recommend using liver MRS for evaluating and grading NAFLD in association with other parameters like serum triglycerides and body mass index grade as this protocol can enhance early detection and provide an accurate grading that will lead to a proper management of this disease. |
| References: | J Gastroenterol. 2012 May;47(5):586-95. (PMID: 22328022) N Engl J Med. 2002 Apr 18;346(16):1221-31. (PMID: 11961152) Ann Hepatol. 2007 Jul-Sep;6(3):161-3. (PMID: 17786142) World J Hepatol. 2018 Aug 27;10(8):530-542. (PMID: 30190781) JAMA. 2015 Jun 9;313(22):2263-73. (PMID: 26057287) Dig Dis. 2010;28(1):155-61. (PMID: 20460905) Clin Mol Hepatol. 2017 Dec;23(4):290-301. (PMID: 28994271) Rom J Morphol Embryol. 2015;56(3):925-35. (PMID: 26662124) J Hepatol. 2005 Sep;43(3):508-14. (PMID: 16006003) Liver Int. 2017 Jan;37 Suppl 1:81-84. (PMID: 28052624) Rom J Morphol Embryol. 2019;60(2):479-486. (PMID: 31658321) Rom J Morphol Embryol. 2012;53(3):609-14. (PMID: 22990555) Liver Int. 2017 Oct;37(10):1544-1553. (PMID: 28544208) Rom J Morphol Embryol. 2018;59(1):297-302. (PMID: 29940641) Hepatology. 2005 Jun;41(6):1313-21. (PMID: 15915461) F1000Res. 2017 Sep 4;6:1630. (PMID: 29093809) Rom J Morphol Embryol. 2008;49(1):13-20. (PMID: 18273497) Iran Red Crescent Med J. 2014 Jan;16(1):e12669. (PMID: 24719704) Radiology. 2013 May;267(2):422-31. (PMID: 23382291) Hepatology. 2003 Jun;37(6):1286-92. (PMID: 12774006) Adv Ther. 2017 Jun;34(6):1291-1326. (PMID: 28526997) J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70. (PMID: 24251707) Proc Nutr Soc. 2013 Nov;72(4):412-9. (PMID: 23668723) Rom J Morphol Embryol. 2010;51(3):509-14. (PMID: 20809028) Med Ultrason. 2016 Jun;18(2):157-62. (PMID: 27239648) World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. (PMID: 29307986) AJR Am J Roentgenol. 2012 Jul;199(1):2-7. (PMID: 22733887) |
| تواريخ الأحداث: | Date Created: 20200805 Date Completed: 20210614 Latest Revision: 20210614 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7728118 |
| DOI: | 10.47162/RJME.61.1.08 |
| PMID: | 32747897 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2066-8279 |
|---|---|
| DOI: | 10.47162/RJME.61.1.08 |